ANVS
Price:
$9.09
Market Cap:
$118.66M
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.[Read more]
Industry
Biotechnology
IPO Date
2020-01-29
Stock Exchange
NYSE
Ticker
ANVS
According to Annovis Bio, Inc.’s latest financial reports and current stock price. The company's current ROE is 2.78%. This represents a change of 2.79% compared to the average of 96.03% of the last 4 quarters.
The mean historical ROE of Annovis Bio, Inc. over the last ten years is 81.44%. The current 2.78% ROE has changed 3.31% with respect to the historical average. Over the past ten years (40 quarters), ANVS's ROE was at its highest in in the June 2024 quarter at 286.74%. The ROE was at its lowest in in the September 2023 quarter at -221.03%.
Average
81.44%
Median
3.46%
Minimum
-88.78%
Maximum
725.14%
Discovering the peaks and valleys of Annovis Bio, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 173.62%
Maximum Annual ROE = 725.14%
Minimum Annual Increase = -1731.18%
Minimum Annual ROE = -88.78%
Year | ROE | Change |
---|---|---|
2023 | 725.14% | -916.77% |
2022 | -88.78% | 173.62% |
2021 | -32.45% | -42.53% |
2020 | -56.46% | -1731.18% |
2019 | 3.46% | -63.18% |
2018 | 9.40% | -4.04% |
The current ROE of Annovis Bio, Inc. (ANVS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
201.30%
5-year avg
110.18%
10-year avg
81.44%
Annovis Bio, Inc.’s ROE is greater than Cassava Sciences, Inc. (-10.98%), greater than Axsome Therapeutics, Inc. (-174.48%), less than Reviva Pharmaceuticals Holdings, Inc. (664.92%), less than Seres Therapeutics, Inc. (313.56%), greater than Anavex Life Sciences Corp. (-30.62%), greater than Iovance Biotherapeutics, Inc. (-65.04%), less than Novavax, Inc. (43.70%), greater than Anixa Biosciences, Inc. (-52.41%), greater than TFF Pharmaceuticals, Inc. (-225.16%), greater than Immunome, Inc. (-157.86%), greater than IN8bio, Inc. (-173.12%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than Inozyme Pharma, Inc. (-68.93%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Galera Therapeutics, Inc. (21.95%), greater than Cue Biopharma, Inc. (-142.93%), greater than Lantern Pharma Inc. (-46.39%), greater than Gracell Biotechnologies Inc. (-37.20%),
Company | ROE | Market cap |
---|---|---|
-10.98% | $1.26B | |
-174.48% | $4.26B | |
664.92% | $32.69M | |
313.56% | $139.89M | |
-30.62% | $579.58M | |
-65.04% | $3.40B | |
43.70% | $1.50B | |
-52.41% | $117.78M | |
-225.16% | $6.83M | |
-157.86% | $696.03M | |
-173.12% | $13.40M | |
-24.63% | $170.93M | |
-68.93% | $273.52M | |
-39.58% | $585.99M | |
-22.40% | $1.29B | |
21.95% | $2.72M | |
-142.93% | $91.52M | |
-46.39% | $35.63M | |
-37.20% | $989.87M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Annovis Bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Annovis Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Annovis Bio, Inc.'s ROE?
How is the ROE calculated for Annovis Bio, Inc. (ANVS)?
What is the highest ROE for Annovis Bio, Inc. (ANVS)?
What is the 3-year average ROE for Annovis Bio, Inc. (ANVS)?
What is the 5-year average ROE for Annovis Bio, Inc. (ANVS)?
How does the current ROE for Annovis Bio, Inc. (ANVS) compare to its historical average?